Treatment-refractory anxiety; definition, risk factors, and treatment challenges

被引:0
|
作者
Roy-Byrne, Peter [1 ,2 ]
机构
[1] Univ Washington, Harborview Med Ctr, Sch Med, Psychiat, Seattle, WA 98104 USA
[2] Psychiat Med Associates, Seattle, WA USA
关键词
anxiety; refractory; pseudo-resistance; CBT; antidepressant; benzodiazepine; COGNITIVE-BEHAVIORAL THERAPY; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; OBSESSIVE-COMPULSIVE DISORDER; GENERALIZED SOCIAL PHOBIA; SUBSTANCE USE DISORDERS; SEROTONIN REUPTAKE INHIBITORS; MAJOR DEPRESSIVE DISORDER; TASK-FORCE REPORT;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A sizable proportion of psychiatric patients will seek clinical evaluation and treatment for anxiety symptoms reportedly refractory to treatment. This apparent lack of response is either due to "pseudo-resistance" (a failure to have received and adhered to a recognized and effective treatment or treatments for their condition) or to true "treatment resistance." Pseudo-resistance can be due to clinician errors in selecting and delivering an appropriate treatment effectively, or to patient nonadherence to a course of treatment. True treatment resistance can be due to unrecognized exogenous anxiogenic factors (eg, caffeine overuse, sleep deprivation, use of alcohol or marijuana) or an incorrect diagnosis (eg, atypical bipolar illness, occult substance abuse, attention deficit-hyperactivity disorder). Once the above factors are eliminated, treatment should focus on combining effective medications and cognitive behavioral therapy, combining several medications (augmentation), or employing novel medications or psychotherapies not typically indicated as first-line evidence-based anxiety treatments. (C) 2015, AICH -Servier Research Group
引用
收藏
页码:191 / 206
页数:16
相关论文
共 50 条
  • [41] CLOZAPINE AND ECT FOR TREATMENT-REFRACTORY SCHIZOPHRENIA
    Siskind, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2017, 51 : 86 - 86
  • [42] Treatment-refractory warts associated with fingolimod
    Sahi, Nitin
    Al-Araji, Sarmad A.
    Ciccarelli, Olga
    Chard, Declan T.
    Trip, S. Anand
    PRACTICAL NEUROLOGY, 2022, 22 (06) : 503 - 504
  • [43] Treatment-Refractory Schizophrenia: A Clinical Conundrum
    Nasrallah, Henry A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (09) : E1142 - E1142
  • [44] Meningioma Presenting With Treatment-Refractory Depression
    Huang, Tai-Han
    Hong, Chen-Jee
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2014, 26 (01) : E24 - E25
  • [45] Pegloticase In Treatment-Refractory Chronic Gout
    Lyseng-Williamson, Katherine A.
    DRUGS, 2011, 71 (16) : 2179 - 2192
  • [46] THE USE OF CLOZAPINE IN TREATMENT-REFRACTORY SCHIZOPHRENIA
    KUOPPASALMI, K
    RIMON, R
    NAUKKARINEN, H
    LANG, S
    SANDQVIST, A
    LEINONEN, E
    SCHIZOPHRENIA RESEARCH, 1993, 10 (01) : 29 - 32
  • [47] Dupilumab for treatment-refractory prurigo nodularis
    Kovacs, Balint
    Rose, Ellen
    Kuznik, Nadine
    Shimanovich, Iakov
    Zillikens, Detlef
    Ludwig, Ralf J.
    Thaci, Diamant
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 (06):
  • [48] Repurposing quinacrine for treatment-refractory cancer
    Oien, Derek B.
    Pathoulas, Christopher L.
    Ray, Upasana
    Thirusangu, Prabhu
    Kalogera, Eleftheria
    Shridhar, Viji
    SEMINARS IN CANCER BIOLOGY, 2021, 68 : 21 - 30
  • [49] Benefit of dupilumab in treatment-refractory ABPA
    Nugent, Matthew J.
    Jones, Reece A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (06) : 458 - 458
  • [50] Treatment-refractory progressive nodular histiocytosis
    Seegraeber, Marlene
    Engels, Laura
    Flaig, Michael J.
    HAUTARZT, 2020, 71 (SUPPL 1): : 2 - 5